Comparison · NCT00153101-63ce08d5
Telmisartan (TRANSCEND) vs Placebo (TRANSCEND): TRANSCEND. Cardiovascular Death
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Telmisartan (TRANSCEND) vs Placebo (TRANSCEND): TRANSCEND. Cardiovascular Death. Trial comparisons, record NCT00153101-63ce08d5. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00153101-63ce08d5
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.0768 | 0.0678 | 0.087 | wilson | |
| Risk in group 2 | 0.075 | 0.0661 | 0.0851 | wilson | |
| Risk difference, group 1 minus group 2 | 0.00181 | -0.0117 | 0.0153 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.02 | 0.857 | 1.22 | log | |
| Odds ratio, group 1 over group 2 | 1.03 | 0.847 | 1.24 | log | |
| Number needed to treat, for one more participant with the outcome on Telmisartan (TRANSCEND) than on Placebo (TRANSCEND) | 552 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Telmisartan (TRANSCEND) | Telmisartan 80mg tablet, one tablet administered once daily in the morning. | 227 | 2,954 | OG000 |
| Group 2 | Placebo (TRANSCEND) | Telmisartan 80mg placebo tablet, one tablet administered once daily in the morning. | 223 | 2,972 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- TRANSCEND. Cardiovascular Death
- Description
Telmisartan Randomized Assessment Study in Angiotension Converting Enzyme inhibitor intolerant subjects with cardiovascular disease (TRANSCEND). Time to the first event analysis of the endpoint cardiovascular death.
- Time frame
- 56 months
- Population
- FAS of the TRANSCEND trial
Source ClinicalTrials.gov
Trial
- Title
Effectiveness and Safety of Ramipril Alone Compared With Telmisartan Alone and in Combination With Ramipril in Patients at High Risk for Cardiovascular Events. Patients Intolerant to Ramipril Were Entered in TRANSCEND, Telmisartan Compared to Placebo.
- NCT number
- NCT00153101
- Phases
- PHASE4
- Conditions
- Cardiovascular Diseases
- Interventions
- Telmisartan, Combination of Telmisartan and Ramipril, Ramipril
- Lead sponsor
- Boehringer Ingelheim
- Results first posted
- 2009-08-25
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00153101?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00153101-63ce08d5